U.S. SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 12b-25
SEC File No:
NOTIFICATION OF LATE FILING 0-12968
Form 10-Q or 10-QSB
For Period Ended September 30, 1996
Nothing in this form shall be construed to imply that the Commission
has verified any information contained herein.
If the notification relates to a portion of the filing checked above,
identify the Item(s) to which the notification relates:
Not applicable. The filing relates to the entire Form 10-QSB.
Part I--Registrant Information
Full Name of Registrant: INMEDICA DEVELOPMENT CORPORATION
Address of Principal Executive Office:
60 South 600 East, Suite 150
City, State and Zip Code: Salt Lake City, Utah 84102
Part II--Rules 12b-25(b) and (c)
If the subject report could not be filed without unreasonable effort or
expense and the registrant seeks relief pursuant to Rule 12b-25(b), the
following should be completed. (Check box if appropriate)
[X] (a) The reasons described in reasonable detail in Part III of
this form could not be eliminated without unreasonable effort or
expense;
[X] (b) The subject annual report or semi-annual report/portion thereof will be
filed on or before the fifteenth calendar day following the prescribed due date;
or the subject quarterly report/portion thereof will be filed on or before the
fifth calendar day following the prescribed due date; and
[ ] (c) The accountant's statement or other exhibit required by
Rule 12b-25(c) has been attached if applicable.
1
<PAGE>
Part III--Narrative
State below in reasonable detail the reasons why Form 10-Q or 10-QSB or
portion thereof could not be filed within the prescribed time period.
The reason the report could not be timely filed is that the Company had
granted certain options during the reporting period and was advised
prior to the filing of the need to compute the expense associated with
the options under new regulations. As a result, the filing has been
delayed while the Company obtains software and makes the computation.
Part IV--Other Information
(1) The person to contact in regard to this notification is:
Scott R. Jenkins (801) 531-8300
(2) Have all other periodic reports required under section 13 or 15(d)
of the Securities Exchange Act of 1934 or section 30 of the Investment Company
Act of 1940 during the preceding 12 months or for such shorter period that the
registrant was required to file such report(s) been filed? If the answer is no,
identify report(s). [X] Yes [ ] No
(3) Is it anticipated that any significant change in results of
operations from the corresponding period for the last fiscal year will be
reflected by the earnings statements to be included in the subject report or
portion thereof? [X] Yes [ ] No
If so: attach an explanation of the anticipated change, both
narratively and quantitatively, and, if appropriate, state the reasons why a
reasonable estimate of results cannot be made.
The Company expects to have gross revenues comparable to those received
during the comparable period of 1995. Income from operations is expected to
decrease, however, due to increased research and development expense in the
current year. Net income for the current year is expected to be significantly
reduced from the prior period in that the prior period included extraordinary
gain from debt extinguishment of $188,770, with no comparable gain in the
current year. Pending the computation of the stock option expense, a reasonable
estimate of the quantitative results of operations cannot be made at this time.
2
<PAGE>
INMEDICA DEVELOPMENT CORPORATION
has caused this notification to be signed on its behalf by the undersigned
thereunto duly authorized.
Date: November 14, 1996 By:/s/Larry E. Clark
Larry E. Clark, President
INSTRUCTION: The form may be signed by an executive officer of the registrant or
by any other duly authorized representative. The name and title of the person
signing the form shall be typed or printed beneath the signature. If the
statement is signed on behalf of the registrant by an authorized representative
(other than an executive officer), evidence of the representative's authority to
sign on behalf of the registrant shall be filed with the form.
3
